Liver cirrhosis is characterised by progressive fibrosis, portal hypertension and liver failure. Acute-on-Chronic liver failure is a clinical scenario wherein an acute insult leads to deterioration of underlying liver disease.The chronic liver failure (CLIF) Acute-on-Chronic liver failure (ACLF) in cirrhosis (CANONIC) study has defined ACLF in acute decompensation of cirrhosis bases upon presence and number of organ failure.Septic shock is leading cause of mortality in intensive care units in general population.Cirrhosis is a hyperdynamic circulation which worsens with infection.The choice of vasopressor for treating septic shock in ACLF patients is unclear. While noradrenaline in general is preferred vasopressor, terlipressin improves micro circulation in addition to vasopressor action.We aim to compare terlipressin infusion and noradrenaline in patients of ACLF with septic shock. It shall be a prospective, open label, randomised controlled trial. All patients of cirrhosis presenting with acute decompensation shall be screened for presence of ACLF and septic shock. All patients responsive to fluids, shall be excluded from study.After due consideration of inclusive and exclusive criteria, A total of 60 patients shall be taken , with 30 in each group.As per randomisation technique, group 1 patients shall receive noradrenaline infusion , Group 2 patients shall receive terlipressin infusion. In case of non response, alternate agent will be added after 3 hours.Patients enrolled in study will be followed for assessment of outcomes.The primary outcome shall be taken as response of shock to therapy. The secondary outcome shall be taken as mortality at 3,7,14 and 28 days, duration of hospital stay, cumulative dose of drug, recurrence of events like upper GI bleed , acute kidney injury, hepatic encephalopathy.